Is the Price Right for Aducanumab?

07/27/21 • 37 min

The first new treatment for Alzheimer's, aducanumab, was approved by the Food and Drug Administration on June 7, 2021. This approval did not come without controversy. Learn what the available data show for efficacy and safety and whether or not the current list price of $56,000 per year meets cost-effectiveness thresholds.
Guest
John A Galdo, PharmD, MBA, BCPS, BCGP
Course Content and Developer, CEimpact
Pharmacist, Ross Bridge Pharmacy
CEO, Seguridad
Redeem your CPE or CME credit here!
We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155144694964

References and resources:
Aducanumab for Alzheimer's Disease: Effectiveness and Value. Institute for Clinical and Economic Review. June 30, 2021. https://icer.org/wp-content/uploads/2020/10/ICER_ALZ_Revised_Evidence_Report_06302021.pdf
Continuing Education Information:
Learning Objectives:
1. Discuss the outcomes for phase III trials of aducanumab
2. Define the cost-effectiveness of aducanumab
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-265-H01-P
Initial release date: 7/27/21
Expiration date: 7/27/22
John A. Galdo reports that he is on a speaker's bureau for Novo Nordisk.
Complete CPE & CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Follow CEimpact on Social Media:
LinkedIn
Instagram

Previous Episode

Can Money Buy Health in Heart Failure?

A new study evaluates the cost-effectiveness of dapagliflozin in heart failure. Geoff and Jake continue the conversation from "Home Sweet Home (It's Where the Heart Is)" [Previous Episode] about the role of SGLT-2is in heart failure. This time the conversation is focused on the cost-effectiveness and QALYs. Is the price right for improved care?
Redeem your CPE or CME credit here!
We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155144694964
References and resources:
Parizo JT, Goldhaber-Fiebert JD, Salomon JA, et al. Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. Published online May 26, 2021. doi:10.1001/jamacardio.2021.1437
Continuing Education Information:
Learning Objectives:
1. Define QALY
2. Discuss the cost-effectiveness of dapagliflozin in heart failure
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-264-H01-P
Initial release date: 7/20/21
Expiration date: 7/20/2022
Complete CPE & CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram

Next Episode

COVID-19 Update: Vaccines and the Delta Variant

The delta variant of COVID-19 has put the US in the precarious position of a fourth wave of the disease -- how efficacious are our vaccines against this variant? Also, are any new treatments for early COVID-19 being studied to help continue the fight? Find out more in this episode!
Redeem your CPE or CME credit here!
We want your feedback! Share your feedback and experience with GameChangers! https://www.jotform.com/build/90155144694964
References and resources:
Thompson MG, Burgess JL, Naleway AL, et al. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med. 2021 Jul 22;385(4):320-329. doi: 10.1056/NEJMoa2107058. Epub 2021 Jun 30. PMID: 34192428; PMCID: PMC8262622.
Rossignol J, Matthew C, Oaks J, et al. Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization. medRxiv 2021.04.19.21255441; doi: https://doi.org/10.1101/2021.04.19.21255441

Continuing Education Information:
Learning Objectives:
1. Discuss the differences in effectiveness between the mRNA and adenovirus vaccines for the delta variant of COVID-19
2. Describe the use of nitazoxanide in mild to moderate COVID-19 and barriers to its use
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-XXX-H01-P
Initial release date: 8/31/21
Expiration date: 8/24/22
Complete CPE & CME details can be found here.